Lucid Diagnostics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $4.7M | $4.3M | $2.4M | $377.0K | $500.0K | — |
| Cost of Revenue | — | $6.7M | $7.1M | — | $100.0M | $585.0K | — |
| Gross Profit | — | $-2.0M | $-2.8M | — | $377.0K | $500.0K | — |
| Gross Margin | — | -41.7% | -63.3% | — | 100.0% | 100.0% | — |
| Operating Expenses | |||||||
| Research & Development | — | $5.7M | $6.0M | $7.3M | $11.3M | $9.3M | $5.4M |
| SG&A Expense | — | $23.9M | $20.2M | $19.3M | $24.0M | $21.0K | $7.0K |
| Operating Income | — | $-49.6M | $-46.1M | $-48.5M | $-56.3M | $-27.4M | $-8.3M |
| Operating Margin | — | -1,054.8% | -1,059.6% | -1,996.8% | -14,920.7% | -5,483.8% | — |
| Interest Expense | — | — | $26.0K | $416.0K | $8.0K | $659.0K | — |
| Pretax Income | — | $-58.0M | $-45.5M | $-52.7M | $-56.2M | $-28.1M | $-8.3M |
| Income Tax Expense | — | $0 | $0 | — | — | — | — |
| Net Income | — | $-58.0M | $-45.5M | $-52.7M | $-56.2M | $-28.1M | $-8.3M |
| Net Margin | — | -1,232.7% | -1,047.6% | -2,169.1% | -14,899.5% | -5,615.6% | — |
| EPS (Basic) | — | $-0.69 | $-0.53 | $-0.63 | $-0.78 | $-0.76 | $-0.30 |
| EPS (Diluted) | — | — | $-0.53 | $-0.63 | $-0.78 | $-0.76 | $-0.30 |
| Shares Outstanding (Basic) | 176.9M | 101.9M | 101.0M | 83.5M | 72.3M | 37.2M | 28.2M |
| Shares Outstanding (Diluted) | 176.9M | 101.9M | 101.0M | 83.5M | 72.3M | 37.2M | 28.2M |
| Dividends Per Share | — | — | — | — | — | — | — |